Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the effectiveness of the combination of Naltrexone and Bupropion relative to placebo for reducing binge eating in persons with obesity and binge eating disorder.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Bupropion; Bupropion hydrochloride, naltrexone hydrochoride drug combination; Naltrexone

Criteria

Inclusion Criteria:

• Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)

• BMI between 30 kg/m2 and 50 kg/m2

• Not taking anti-depressant medications

• Read English proficiently enough to read study assessments

• Available for duration of treatment plus follow-up period

• Able to travel to study location (New Haven, CT) for monthly visits

• Agree to study procedures

Exclusion Criteria:

• Medical status judged by study physician as contraindication

• History of seizures

• Past or current anorexia nervosa, bulimia nervosa

• Current medications that influence eating/weight

• Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality) that requires immediate treatment

• Pregnant or breastfeeding